Additional studies have also recommended varying forms of gesture therapy, whereby the patient is instructed to make gestures (either using objects or symbolically meaningful and nonmeaningful gestures) with progressively less cuing from the therapist. Patients with apraxia may need to use a form of alternative and augmentative communication depending on the severity of the disorder. In addition to using gestures as mentioned, patients can also use communication boards or more sophisticated electronic devices if needed.No single type of therapy or approach has been proven as the best way to treat a patient with apraxia, since each patients case varies. One-on-one sessions usually work the best, though, with the support of family members and friends. Since everyone responds to therapy differently, some patients will make significant improvements, while others will make less progress. The overall goal for treatment of apraxia is to treat the motor plans for speech, not treating at the phoneme (sound) level. Individuals with apraxia of speech should receive treatment that focuses on the repetition of target words and rate of speech. The overall goal for treatment of apraxia should be to improve speech intelligibility, rate of speech, and articulation of targeted words. Prognosis
The prognosis for individuals with apraxia varies. With therapy, some patients improve significantly, while others may show very little improvement. Some individuals with apraxia may benefit from the use of a communication aid. However, many people with apraxia are no longer able to be independent.
Individuals ages 21–40 years are most commonly affected.A 2002 study looking at 445 samples of dermatophytes in patients in Goiânia, Brazil found the most prevalent type to be Trichophyton rubrum (49.4%), followed by Trichophyton mentagrophytes (30.8%), and Microsporum canis (12.6%).A 2013 study looking at 5,175 samples of Tinea in patients in Tehran, Iran found the most prevalent type to be Tinea pedis (43.4%), followed by Tinea unguium. (21.3%), and Tinea cruris (20.7%). See also
Mycobiota

References
Further reading
Weitzman I, Summerbell RC (1995). "The dermatophytes". Clinical Microbiology Reviews. 8 (2): 240–259. doi:10.1128/cmr.8.2.240. PMC 172857. PMID 7621400. External links

Tinea photo library at Dermnet